May-Thurner Syndrome Treatment: Stents, Clot Removal, IVUS, Complications, and Long-Term Outcomes

May-Thurner Syndrome (MTS), also called iliac vein compression syndrome, most often refers to compression of the left common iliac vein by the right common iliac artery against the spine. But clinically significant iliac venous obstruction can occur in other configurations as well. The presence of compression on imaging does not automatically mean a patient needs treatment.

May-Thurner anatomy is common; May-Thurner Syndrome is symptomatic

A patient can have substantial iliac-vein narrowing on CT and never develop symptoms. Intervention is generally considered when the anatomy is associated with meaningful venous disease such as persistent leg swelling or pain, venous claudication, skin changes, pelvic collateralization, recurrent DVT, or post-thrombotic syndrome.

1. Conservative management

Patients with mild symptoms and no acute DVT may be managed conservatively with activity, leg elevation, compression garments, and treatment of other venous risk factors. Compression does not need to be stented simply because it exists.

If a patient has a DVT, anticoagulation is usually required regardless of whether the underlying iliac compression is later treated. The choice and duration of anticoagulation depend on whether the clot was provoked, the extent of thrombosis, thrombophilia, pregnancy, bleeding risk, and the intervention performed.

2. Anticoagulation alone for acute DVT

Anticoagulation prevents clot extension and pulmonary embolism and allows the body to gradually remodel thrombus. However, if a major fixed iliac-vein compression remains, anticoagulation alone does not correct that mechanical obstruction. Persistent outflow obstruction can contribute to recurrent thrombosis or chronic post-thrombotic symptoms in some patients.

3. Catheter-directed thrombolysis

Catheter-directed thrombolysis delivers clot-dissolving medication directly into an acute iliofemoral thrombus. It can rapidly reduce clot burden and may improve venous outflow in carefully selected patients with recent, extensive DVT.

The benefit must be balanced against bleeding risk. Thrombolysis is generally not used simply because May-Thurner anatomy exists; it is considered in selected patients with significant acute iliofemoral thrombosis, severe symptoms, low bleeding risk, and a reasonable chance of restoring useful venous flow.

4. Mechanical thrombectomy

Mechanical thrombectomy uses a catheter device to remove thrombus directly, sometimes with little or no thrombolytic medication. It can be attractive when rapid clot removal is needed or when clinicians want to reduce exposure to thrombolytic drugs.

Newer 2026 retrospective data on AngioJet thrombectomy plus iliac stenting in MTS with acute iliofemoral DVT report good short-term clot clearance and clinical improvement, but comparative long-term evidence is still developing. Device-specific risks can include blood loss, hemolysis, kidney injury, vessel injury, embolization, and incomplete clot removal.

5. Iliac vein stenting

Venous stenting is the most established intervention for clinically significant iliac outflow obstruction. A self-expanding venous stent is placed across the compressed segment to keep the vein open and restore flow.

For nonthrombotic iliac vein lesions, many patients experience meaningful improvement in leg swelling, pain, venous claudication, or pelvic collateral symptoms after successful stenting. For thrombotic disease, stenting is typically performed after clot removal when the underlying compression remains.

Why balloon angioplasty alone is usually not enough

Venous compression caused by a crossing artery and chronic fibrosis tends to recoil after simple balloon dilation. That is why stenting, rather than balloon angioplasty alone, is usually required when a fixed symptomatic iliac lesion is being treated.

IVUS: why many venous specialists consider it essential

Intravascular ultrasound (IVUS) images the vein from inside the vessel and can show the true cross-sectional area, severity and length of compression, scar tissue, intraluminal webs, and the relationship of the lesion to the IVC and other veins.

Venography can underestimate disease because it is two-dimensional and depends on contrast flow and projection. IVUS can change stent sizing and landing-zone decisions and is widely used in modern iliac-vein stenting, especially when symptoms and noninvasive imaging do not perfectly match.

How successful are iliac venous stents?

Published outcomes are generally favorable, but results depend heavily on whether the lesion is nonthrombotic or post-thrombotic. Modern venous-stent studies report high one-year patency and meaningful symptom improvement for symptomatic iliofemoral venous obstruction. Nonthrombotic lesions usually have better patency than chronic post-thrombotic disease.

The 2022 pivotal Abre venous stent study showed strong one-year safety and effectiveness in symptomatic iliofemoral obstruction, with clinically meaningful improvement in venous symptoms. Studies of dedicated venous stents have similarly shown high primary patency at one year, though long-term durability beyond several years remains an important research area.

What can go wrong with a venous stent?

Potential complications include stent thrombosis, in-stent restenosis, underexpansion, migration, fracture, extension too far into the IVC, 'jailing' the opposite iliac vein, recurrent DVT, need for repeat angioplasty or additional stents, access-site bleeding, and persistent symptoms despite a patent stent.

Stent migration is uncommon but can be life-threatening if a stent travels into the heart or pulmonary circulation. The risk is influenced by sizing, stent type, lesion characteristics, and technique.

Contralateral DVT and the IVC landing zone

A left iliac stent often needs to extend slightly into the IVC to fully cover the compressed segment. If it protrudes too far or is poorly positioned, it can obstruct flow from the right iliac vein. This is why precise imaging, sizing, and landing-zone planning are critical.

Stent thrombosis and restenosis

A stent can narrow or occlude because of thrombosis, scar tissue, poor inflow from the leg veins, inadequate lesion coverage, or an untreated downstream or upstream problem. Chronic post-thrombotic disease has a higher failure risk than a purely nonthrombotic compression.

Failed venous stents can sometimes be reopened with thrombectomy, thrombolysis, angioplasty, or additional stenting, but chronic stent occlusion can be difficult to treat and may require specialized venous reconstruction.

Anticoagulation and antiplatelet therapy after stenting

There is no single universally accepted medication regimen after iliac vein stenting. Some patients receive anticoagulation, some antiplatelet therapy, and some both for a period of time. The plan depends on whether the patient had a DVT, thrombophilia, prior clotting history, bleeding risk, and the treating center's protocol.

A patient stented for a nonthrombotic lesion may not need the same long-term anticoagulation as a patient treated after an extensive acute DVT. Medication decisions should be individualized.

Pregnancy and May-Thurner Syndrome

Pregnancy can increase venous compression because of the enlarging uterus and also increases blood clotting tendency. A patient with previously silent May-Thurner anatomy may first become symptomatic during pregnancy.

Patients with a prior iliac stent can often have successful pregnancies, but management may include closer surveillance, compression, and anticoagulation depending on the patient's thrombosis history and obstetric risk. Evidence is still based mostly on small series and expert experience rather than randomized trials.

Children and adolescents

May-Thurner Syndrome does occur in adolescents, particularly when they present with unexplained extensive left iliofemoral DVT. Published pediatric series describe treatment with thrombolysis followed by iliac stenting in selected cases.

In younger patients, the decision to place a permanent venous stent deserves extra caution because of growth, decades of future device life, pregnancy considerations, and limited pediatric long-term data.

Surgery and bypass

Before endovascular treatment became common, open venous bypass and surgical decompression were used more often. Surgical options can include iliofemoral or iliocaval bypass and other venous reconstructions. These are now generally reserved for unusual anatomy, failed endovascular treatment, or complex chronic occlusions.

Pelvic symptoms and overlapping venous disease

May-Thurner Syndrome can contribute to pelvic collateral veins and may coexist with Nutcracker Syndrome, gonadal-vein reflux, or other pelvic venous disorders. Treating only one compression may not resolve all symptoms if more than one outflow pathway is abnormal.

This is especially important for VCA because many patients do not fit neatly into a single compression diagnosis. A patient with pelvic pain may need evaluation of the iliac veins, left renal vein, gonadal veins, and pelvic collaterals rather than assuming all symptoms come from one lesion.

Why a patent stent does not always mean the patient is symptom-free

Some patients continue to have pain, swelling, pelvic symptoms, or exercise intolerance despite a technically patent stent. Residual post-thrombotic damage, pelvic venous reflux, another compression, nerve pain, lymphatic issues, or musculoskeletal causes may still contribute.

Questions families may want to ask before iliac vein stenting

Is the iliac compression truly causing symptoms or is it an incidental finding? Is there an acute or chronic DVT? Will IVUS be used? What percentage or area reduction is considered significant at this center? What stent type and diameter will be used? Where will the stent land relative to the IVC? What is this operator's stent thrombosis and reintervention rate? What anticoagulation or antiplatelet plan is recommended afterward? Has Nutcracker Syndrome or pelvic venous reflux also been evaluated?

Selected peer-reviewed research

Radaideh Q, et al. Iliac vein compression: epidemiology, diagnosis and treatment. Vasc Health Risk Manag. 2019. DOI: 10.2147/VHRM.S203349

Abre Venous Self-Expanding Stent pivotal study. Circulation: Cardiovascular Interventions. 2022. DOI: 10.1161/CIRCINTERVENTIONS.121.010960

Evolving Concepts in the Diagnosis and Management of May-Thurner Syndrome. J Clin Interv Radiol ISVIR. 2017. DOI: 10.1055/s-0036-1597954

Current Status and Prospect of Stent Placement for May-Thurner Syndrome. Curr Med Sci. 2021. DOI: 10.1007/s11596-021-2481-4

Endovascular Management of May-Thurner Syndrome. Medicine. 2016. DOI: 10.1097/MD.0000000000002541

May-Thurner syndrome (iliac vein compression) and thrombosis in adolescents. Pediatr Blood Cancer. 2005. DOI: 10.1002/pbc.20728

Management of May Thurner Syndrome in Pregnant Patients. J Cardiovasc Dev Dis. 2022. DOI: 10.3390/jcdd9120410

Slippery Stents: A Case Report and Review of the Literature Describing Patients with May-Thurner Syndrome That Experienced Stent Migration. Case Rep Vasc Med. 2019. DOI: 10.1155/2019/7606727

Bottom line

For symptomatic May-Thurner Syndrome, modern therapy is usually endovascular rather than open surgery. The key decisions are whether the anatomy is truly clinically significant, whether an acute or chronic clot is present, how the lesion is characterized with IVUS, and whether stenting is likely to improve venous outflow enough to justify a permanent implant. Nonthrombotic disease generally has better outcomes than heavily post-thrombotic disease.

Important limitation

Many May-Thurner studies combine different types of iliac venous obstruction, stent platforms, and clot histories. Outcome percentages should not be applied to every patient equally. Long-term data in children, adolescents, pregnancy, and patients with multiple vascular compressions are especially limited.